By August 2017, Hebei Yanda Lu Daopei Hospital has treated approximately 220 patients by using CAR-T technology in clinical treatment.
Our hospital has performed the most CAR-T cases in China and has accumulated rich clinical experience. CAR-T therapy shows incredible effects in clinical application. For instance, the complete remission rate for refractory and relapsed B-cell acute lymphoblastic leukemia (B-ALL) can reach as high as 90%. In addition, our achievements in CAR-T bridging to HSCT have also received international recognition and approval.
Beijing Lu Daopei Hospital is completed and will open soon.
The 5th Lu Daopei Hematology Summit Forum
The Fifth Lu Daopei Hematology Summit Forum and the First Academic Meeting of Blood Disease Professional Committee of China Non-public Medical Institution Association was held from June 30 to July 1st, 2017 at the Beijing International Convention Center.
Charitable Donation by Caring Patients
In March 2017, Mr. Zhang Shanhua, an entrepreneur, donated 16 million CNY to the V Love Fund for the Blood and marrow transplantation for children diagnosed with leukemia at the Lu Daopei Hospital.